COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

NCT ID: NCT05434689

Last Updated: 2026-01-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-18
• Study Completion Date: 2026-10-31

Brief Summary

Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status.

Given its favorable toxicity profile, the convenience of oral administration, and compelling single agent activity even in heavily pretreated MM, iberdomide is likely amenable to long term therapy in patients with high-risk of relapse/progression identified by the persistence of MRD(+). The investigators intend to develop combination(s) of iberdomide with other agents with complementary mechanism of action in the consolidation setting post AHCT in order to achieve and sustain MRD (-).

Conditions

Multiple Myeloma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Iberdomide, Daratumumab and Dexamethasone (Regimen A)

Iberdomide dosed according to cohort assignment days 1-21. Dexamethasone 40 mg oral or intravenously (20 mg for participants 70 or older) on days 1,8,15 and 22 Darartumumab and hyalurnonidase-fihj 1,800mg/30,000 units subcutaneously on days 1,8,15,22 (cycles 1,2) or on days 1,15 (cycles 3-6)

Group Type: EXPERIMENTAL

Daratumumab

Intervention Type: DRUG

Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma

Dexamethasone

Intervention Type: DRUG

Corticosteroid active against multiple myeloma in combination with other agents

Iberdomide

Intervention Type: DRUG

Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.

Iberdomide, Carfilzomib, Daratumumab and Dexamethasone (Regimen B)

Iberdomide dosed according to cohort assignment days 1-21. Dexamethasone 40 mg oral or intravenously (20 mg for participants 70 or older) on days 1,8,15 and 22 Darartumumab and hyalurnonidase-fihj 1,800mg/30,000 units subcutaneously on days 1,8,15,22 (cycles 1,2) or on days 1,15 (cycles 3-6) Carfilzomib dosed intravenously dosed according to cohort assignment on days 1, 8, 15 (Consistent with standard practice, the very first dose of carfilzomib (cycle 1 day 1) must be 20 mg/m\^2).

Group Type: EXPERIMENTAL

Daratumumab

Intervention Type: DRUG

Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma

Dexamethasone

Intervention Type: DRUG

Corticosteroid active against multiple myeloma in combination with other agents

Carfilzomib

Intervention Type: DRUG

Second generation proteasome inhibitor with activity in multiple myeloma

Iberdomide

Intervention Type: DRUG

Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.

Interventions

Daratumumab

Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma

Intervention Type: DRUG

Dexamethasone

Corticosteroid active against multiple myeloma in combination with other agents

Intervention Type: DRUG

Carfilzomib

Second generation proteasome inhibitor with activity in multiple myeloma

Intervention Type: DRUG

Iberdomide

Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age >18 years with no upper age limit

2. Confirmation of newly diagnosed multiple myeloma (MM) with 1-2 prior regimens utilized in induction that included an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI) combined or in different regimens

3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

4. Prior AHCT 100-180 days prior to initiation of protocol-directed therapy

5. MRD ≥ 10^-5 by clonoSEQ® NGS platform, determined 60-120 days after AHCT as part of the usual care.

6. No prior disease progression (either before or since AHCT)

7. Overall response (i.e post-AHCT compared to historical baseline prior to initiation of any therapy for MM) ≥ PR.

8. Measurable disease at the time of the initial diagnosis (i.e. prior to starting any therapy for MM) meeting at least one of the following criteria:

• Serum monoclonal (M) protein ≥1.0 g/dl

• 200 mg of M protein/24h in the urine
• Difference between involved and uninvolved free light chain ≥10 mg/dL and abnormal kappa to lambda ratio.

9. Adequate hepatic function evidenced by AST and ALT ≤ 3 x ULN and bilirubin ≤ 1.5 ULN.

10. Adequate bone marrow function evidenced by platelets ≥ 75,000 /mm3 (without transfusion of platelets in the prior 7 days) and absolute neutrophil count ≥ 1,000/mm3.

11. Creatinine clearance (CrCl) ≥ 40 mL/minute within 28 days prior to start of therapy either measured or calculated using standard Cockcroft and Gault formula (available in https://www.kidney.org/professionals/KDOQI/gfr_calculatorCoc ).

12. Females of childbearing potential (FCBP) must have two negative pregnancy tests as verified by the investigator and agree to ongoing pregnancy testing and to practice contraception during treatment. Male subjects must agree to practice contraception and refrain from donating sperm during treatment.

13. In line with the higher incidence of MM in Blacks, and to address the historical underrepresentation of ethnical minorities in MM trials, at least 25% of the enrolled patients will be of ethnical minorities.

14. Written informed consent in accordance with federal, local, and institutional guidelines.

Exclusion Criteria

1. Diagnosis of amyloidosis, POEMS, Waldenstrom's macroglobulinemia, plasma cell leukemia or smoldering multiple myeloma (i.e. never evolved to active myeloma).

2. Major surgery or radiotherapy within 28 days of starting protocol-directed treatment.

3. Acute active infection requiring treatment within 14 days of starting protocol-directed treatment.

4. Current or prior involvement of central nervous system by multiple myeloma.

5. MM refractory to prior CD38 monoclonal antibody therapy and/or to carfilzomib (prior exposure allowed). Refractoriness here is defined as not achieving at least a PR in a regimen containing the agent or disease progression < 60 days from last dose of the agent.

6. Pregnant or lactating females.

7. Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.

8. Seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy).

9. Unstable angina or myocardial infarction within 4 months prior to starting protocol-directed treatment, NYHA Class II, III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker.

10. A prolongation of QT interval on screening electrocardiogram (ECG) as defined by corrected QT interval (QTc) > 480 ms using Fridericia's QT correction formula.

11. Cerebrovascular disease manifested as prior stroke at any time or TIA in the 12 months prior to initiation of therapy.

12. Uncontrolled hypertension (per investigator assessment, despite optimal medical management)

13. Diagnosis of interstitial lung disease

14. Nonhematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or localized thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas.

15. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 28 days prior to starting protocol-directed treatment.

16. For regimen B - Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).

17. Contra indication or intolerance to required supportive care medications (Aspirin and Acyclovir)

18. Concomitant use of strong inhibitors or inducers of CYP3A4, P-gp, or BCRP, or BCRP substrate with a narrow therapeutic index, for at least 14 days or 5 half-lives (whichever is shorter). (consult https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers )

19. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent Diagnosis of amyloidosis, POEMS, Waldenstrom's macroglobulinemia.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

coMMit Myeloma Trials

UNKNOWN

Sponsor Role: collaborator

University of Alabama at Birmingham

OTHER

Sponsor Role: lead

Responsible Party

Luciano Jose Costa, MD

Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Luciano Costa, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

Locations

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status: RECRUITING

Duke University

Durham, North Carolina, United States

Site Status: NOT_YET_RECRUITING

Ohio State University Medical College

Columbus, Ohio, United States

Site Status: RECRUITING

Oregon Health and Science University

Portland, Oregon, United States

Site Status: RECRUITING

Vanderbilt University Medical College

Nashville, Tennessee, United States

Site Status: NOT_YET_RECRUITING

University of Wisconsin

Madison, Wisconsin, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Luciano Costa, MD

Role: CONTACT

ljcosta@uabmc.edu

205-934-9695

Margaret A Thomas, MPH

Role: CONTACT

margaretathomas@uabmc.edu

Facility Contacts

Luciano Costa, MD

Role: primary

ljcosta@uabmc.edu

2059349695

Yubin Kang, MD

Role: primary

yubin.kang@duke.edu

(919) 668-2331

Naresh Bumma, MD

Role: primary

naresh.bumma@osumc.edu

Rebecca Silbermann, MD

Role: primary

silbermr@ohsu.edu

Bhagirathbhai Dholaria, MD

Role: primary

bhagirath.r.dholaria@vumc.edu

Natalie Callander, MD

Role: primary

nsc@medicine.wisc.edu

Other Identifiers

Amgen, Inc

Identifier Type: OTHER

Identifier Source: secondary_id

BMS

Identifier Type: OTHER

Identifier Source: secondary_id

UAB-21113

Identifier Type: -

Identifier Source: org_study_id